Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 53 Results

Title
Intervention Indication Therapeutic Area Year Actions
Vepdegestrant for previously treated locally advanced or metastatic ER+/HER2– breast cancer Vepdegestrant (ARV-471;PF-07850327) Breast cancer Breast Cancer 2023 View  |  Download
Veliparib in Combination with Carboplatin and Paclitaxel for Breast Cancer – First to Third Line Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Breast cancer Breast Cancer 2017 View  |  Download
Tucatinib with trastuzumab emtansine for treating unresectable, locally advanced or metastatic HER2 positive breast cancer Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) , Tucatinib (ONT-380) Breast cancer Breast Cancer 2022 View  |  Download
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of unresectable locally advanced or metastatic HER2-positive breast cancer Pertuzumab (Perjeta; R-1273) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380) Breast cancer Breast Cancer 2023 View  |  Download
Tucatinib in addition to trastuzumab and capecitabine for advanced breast cancer Capecitabine (Xeloda) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380) Breast cancer Breast Cancer 2020 View  |  Download
Trastuzumab emtansine in combination with pertuzumab for HER2-positive early breast cancer - adjuvant therapy Pertuzumab (Perjeta; R-1273) , Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) Breast cancer Breast Cancer 2019 View  |  Download
Trastuzumab Emtansine for HER2-positive breast cancer - adjuvant Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) Breast cancer Breast Cancer 2018 View  |  Download
Trastuzumab duocarmazine for third-line treatment of HER2-positive unresectable metastatic breast cancer Trastuzumab duocarmazine Breast cancer Breast Cancer 2023 View  |  Download
Trastuzumab deruxtecan neoadjuvant therapy for high-risk HER2-positive early stage breast cancer Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2023 View  |  Download
Trastuzumab deruxtecan for unresectable or metastatic HER2-low (HR+/-) breast cancer – after chemotherapy Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2021 View  |  Download
1 2 3 5 6
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications